Streetbeat News

Analyst Ratings

ABBV

AbbVie (NYSE:ABBV) was analyzed by 7 analysts, showing a mix of bullish to bearish sentiments. The average 12-month price target is $171.57, with a high of $196.00 and a low of $150.00, slightly down from the previous $173.40. Analysts from Barclays, HSBC, Goldman Sachs, Raymond James, Deutsche Bank, and Morgan Stanley have updated their ratings and price targets. AbbVie's financial performance shows a revenue decline of -5.97% for the quarter ending September 30, 2023, but strong net margin and ROE. The company's debt-to-equity ratio is high at 5.02, indicating potential financial challenges.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 2:01 pm

DNA

Goldman Sachs analyst Matthew Sykes has maintained a Sell rating on Ginkgo Bioworks Holdings (NYSE:DNA) and reduced the price target from $1.25 to $1.1.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 2:00 pm

BL

Five analysts have recently updated their ratings on BlackLine (NASDAQ:BL), with a mix of bullish to bearish sentiments. The average 12-month price target is now $62.6, up from $56.67, with a high estimate of $81.00 and a low of $53.00. Analyst actions include adjustments to ratings and price targets, reflecting changes in market dynamics and company performance. BlackLine, a SaaS provider for financial accounting solutions, shows strong financial health with a 12.24% revenue growth rate, a net margin of 7.91%, and an ROE of 6.08%, but faces challenges with a high debt-to-equity ratio of 6.54.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 2:00 pm

PTC

Analysts have updated their ratings and price targets for PTC (NASDAQ:PTC), with a mix of bullish and somewhat bullish perspectives. The average 12-month price target is now $184.62, up from $165.86, indicating an 11.31% increase. Analysts from firms like BMO Capital, Baird, Keybanc, Piper Sandler, JP Morgan, and Oppenheimer have raised their price targets, reflecting a positive outlook on PTC's performance. Despite positive revenue growth, PTC's financials show challenges in profitability and efficiency, with below-industry-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 2:00 pm

ZION

Zions Bancorp (NASDAQ:ZION) received mixed analyst ratings over the last three months, with 9 analysts offering diverse opinions. The average 12-month price target is $43.33, up from the previous $37.67. Analysts from firms including Wedbush, Truist Securities, Barclays, Goldman Sachs, Baird, Wells Fargo, and Citigroup have provided updates, with some raising and others maintaining their price targets. Zions Bancorp is a regional U.S. bank with a market cap below industry average, a recent revenue decline of -7.61%, a net margin of 21.83%, an exceptional ROE of 3.44%, a below-average ROA of 0.19%, and a conservative debt-to-equity ratio of 0.11.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 2:00 pm

LLY

Eli Lilly (NYSE:LLY) has received mixed analyst ratings over the last quarter, with 8 analysts offering varying opinions. The average 12-month price target is $635.88, with a high of $722.00 and a low of $535.00, marking a 2.4% decrease from the previous average target of $651.50. Analysts from Barclays, Daiwa Capital, Truist Securities, Cantor Fitzgerald, Deutsche Bank, and Morgan Stanley have provided updates, with some maintaining and others raising their price targets. Eli Lilly's financial performance shows strong revenue growth but below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 2:00 pm

RBLX

Benchmark analyst Mike Hickey has reiterated a Buy rating on Roblox Corporation (NYSE:RBLX) and maintained a price target of $46.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:55 pm

BL

Goldman Sachs analyst Adam Hotchkiss has maintained a Sell rating on BlackLine (NASDAQ:BL) but increased the price target from $49 to $54.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:51 pm

SGMT

JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Sagimet Biosciences (NASDAQ:SGMT) and increased the price target from $31 to $47, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:45 pm

PHVS

JMP Securities analyst Jonathan Wolleben has maintained a Market Outperform rating on Pharvaris (NASDAQ:PHVS) and increased the price target from $40 to $49.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 1:42 pm